Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIF - Post by User

IMV Inc > Purchase of IP
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Comment by Jthom376on Sep 06, 2023 7:35am
156 Views
Post# 35621386

RE:RE:RE:RE:Purchase of IP

RE:RE:RE:RE:Purchase of IP

2010 agreement between Merck and IMV. 

Seems the indicate a clause around bankruptcy... in that Merck would retain rights. 


Mav was never owned by IMV... had been granted development rights from Merck...
along with commercialization rights if it progressed... bankruptcy seemed to negate all of that. 


if MAV works... how convenient for Merck 

https://fintel.io/doc/sec-imv-inc-1734768-ex42-2023-march-16-19432-8223

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities